Phase I Dose-Escalation Study of EZN-2208 (PEG-SN38), a Novel Conjugate of Poly(ethylene) Glycol and SN38, Administered Weekly in Patients With Advanced Cancer

per Patnaik, Amita, Papadopoulos, Kyriakos P., Tolcher, Anthony W., Beeram, Muralidhar, Urien, Saïk, Schaaf, Larry J., Tahiri, Sanaa, Bekaii-Saab, Tanios, Lokiec, François M., Rezaï, Keyvan, Buchbinder, Aby
Publicat 2013

Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers

per Cottu, Paul H., Bonneterre, Jacques, Varga, Andrea, Campone, Mario, Leary, Alexandra, Floquet, Anne, Berton-Rigaud, Dominique, Sablin, Marie-Paule, Lesoin, Anne, Rezai, Keyvan, Lokiec, François M., Lhomme, Catherine, Bosq, Jacques, Bexon, Alice S., Gilles, Erard M., Proniuk, Stefan, Dieras, Veronique, Jackson, David M., Zukiwski, Alexander, Italiano, Antoine
Publicat a PLoS One (2018)